A Machine Learning approach for assessing drug development risk
Vergetis, V.; Liaropoulos, G.; Georganaki, M.; Dimakakos, A.; Skaltsas, D.; Gorgoulis, V. G.; Tsirigos, A.
Show abstract
Characterizing drug development risk - the probability that a drug will eventually receive regulatory approval - has been notoriously hard given the complexities of drug biology and clinical trials. This often leads to an inefficient allocation of resources, and an overall reduction in R&D productivity. We propose a Machine Learning (ML) approach that provides a more accurate and unbiased estimate of drug development risk than traditional models.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Two-step multi-omics modelling of drug sensitivity in cancer cell lines to identify driving mechanisms 94%
- A cautionary tale about properly vetting datasets used in supervised learning predicting metabolic pathway involvement 94%
- Predicting drug sensitivity of cancer cells based on DNA methylation levels 94%
Similar papers in this journal
- Combining symbolic regression with the Cox proportional hazards model improves prediction of heart failure deaths 93%
- On the predictability of postoperative complications for cancer patients: a Portuguese cohort study 92%
- Addressing Label Noise for Electronic Health Records: Insights from Computer Vision for Tabular Data 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.